{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,27]],"date-time":"2026-10-27T23:37:35Z","timestamp":1793144255792,"version":"4.5.0"},"reference-count":141,"publisher":"MDPI AG","issue":"24","license":[{"start":{"date-parts":[[2025,12,17]],"date-time":"2025-12-17T00:00:00Z","timestamp":1765929600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["IJMS"],"abstract":"<jats:p>Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) and newer incretin-based co-agonists have transformed obesity and type 2 diabetes (T2D) management, achieving unprecedented weight loss and cardiometabolic benefits. However, their effects on body composition, particularly lean and skeletal muscle mass, remain incompletely defined. In this current review, we examined the influence of GLP-1 RAs and incretin hormone agonists on lean tissue, integrating physiological, clinical, and mechanistic perspectives. We first outlined the physiology of incretin hormones, with emphasis on their metabolic roles and potential relevance to muscle health. We then discussed sarcopenia and sarcopenic obesity as conditions of rising clinical concern, given their overlap with obesity and metabolic disease. Evidence from preclinical studies and randomized clinical trials indicates that while GLP-1-based therapies predominantly reduce adipose tissue, including visceral and ectopic depots, but they also produce absolute reductions in lean mass, generally representing 20\u201330% of total weight loss. The extent to which these changes translate into impaired muscle function or increased vulnerability to frailty remains unclear. Preservation of lean and skeletal muscle mass is a critical yet underexplored aspect of incretin-based weight loss. Current studies are constrained by methodological heterogeneity, small sample sizes, and limited assessment of functional outcomes. Data on dual and triple agonists are emerging but remain limited. Future research should integrate standardized body-composition measures, mechanistic exploration, and adjunctive interventions such as resistance training or protein optimization.<\/jats:p>","DOI":"10.3390\/ijms262412130","type":"journal-article","created":{"date-parts":[[2025,12,17]],"date-time":"2025-12-17T10:41:23Z","timestamp":1765968083000},"page":"12130","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":11,"title":["The Influence of Glucagon-like Peptide-1 Receptor Agonists and Other Incretin Hormone Agonists on Body Composition"],"prefix":"10.3390","volume":"26","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-2632-0742","authenticated-orcid":false,"given":"Lampros","family":"Chrysavgis","sequence":"first","affiliation":[{"name":"First Department of Internal Medicine, Medical School, National and Kapodistrian University of Athens, General Hospital Laiko, 115 27 Athens, Greece"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Niki Gerasimoula","family":"Mourelatou","sequence":"additional","affiliation":[{"name":"First Department of Internal Medicine, Medical School, National and Kapodistrian University of Athens, General Hospital Laiko, 115 27 Athens, Greece"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6898-1357","authenticated-orcid":false,"given":"Maria-Evangelia","family":"Koloutsou","sequence":"additional","affiliation":[{"name":"First Department of Propaedeutic Internal Medicine, Medical School, National and Kapodistrian University of Athens, General Hospital Laiko, 115 27 Athens, Greece"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4465-022X","authenticated-orcid":false,"given":"Sophia","family":"Rozani","sequence":"additional","affiliation":[{"name":"First Department of Internal Medicine, Medical School, National and Kapodistrian University of Athens, General Hospital Laiko, 115 27 Athens, Greece"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3645-582X","authenticated-orcid":false,"given":"Evangelos","family":"Cholongitas","sequence":"additional","affiliation":[{"name":"First Department of Internal Medicine, Medical School, National and Kapodistrian University of Athens, General Hospital Laiko, 115 27 Athens, Greece"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2025,12,17]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"108045","DOI":"10.1016\/j.phrs.2025.108045","article-title":"History of glucagon-like peptide-1 receptor agonists","volume":"222","author":"Darwish","year":"2025","journal-title":"Pharmacol. Res."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"103363","DOI":"10.1016\/j.eclinm.2025.103363","article-title":"The expanding role of GLP-1 receptor agonists: A narrative review of current evidence and future directions","volume":"86","author":"Moiz","year":"2025","journal-title":"eClinicalMedicine"},{"key":"ref_3","unstructured":"Lobstein, T., Jackson-Leach, R., Powis, J., Brinsden, H., and Gray, M. (2023). World Obesity Atlas 2023, World Obesity Federation."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"100375","DOI":"10.1016\/j.metop.2025.100375","article-title":"Obesity: Prevalence, causes, consequences, management, preventive strategies and future research directions","volume":"27","author":"Ahmed","year":"2025","journal-title":"Metab. Open"},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"C375","DOI":"10.1152\/ajpcell.00379.2020","article-title":"Adipose tissue inflammation and metabolic dysfunction in obesity","volume":"320","author":"Kawai","year":"2021","journal-title":"Am. J. Physiol. Cell Physiol."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"595","DOI":"10.1016\/S2213-8587(21)00179-0","article-title":"Effects of liraglutide on visceral and ectopic fat in adults with overweight and obesity at high cardiovascular risk: A randomised, double-blind, placebo-controlled, clinical trial","volume":"9","author":"Neeland","year":"2021","journal-title":"Lancet Diabetes Endocrinol."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"2049","DOI":"10.1038\/s41591-024-02996-7","article-title":"Long-term weight loss effects of semaglutide in obesity without diabetes in the SELECT trial","volume":"30","author":"Ryan","year":"2024","journal-title":"Nat. Med."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1111\/dom.15728","article-title":"Changes in lean body mass with glucagon-like peptide-1-based therapies and mitigation strategies","volume":"26","author":"Neeland","year":"2024","journal-title":"Diabetes Obes. Metab."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1111\/dom.16012","article-title":"Characterizing body composition modifying effects of a glucagon-like peptide 1 receptor-based agonist: A meta-analysis","volume":"27","author":"Jiao","year":"2025","journal-title":"Diabetes Obes. Metab."},{"key":"ref_10","doi-asserted-by":"crossref","unstructured":"Chrysavgis, L., Mourelatou, N.G., and Cholongitas, E. (2025). Glucagon-like Peptide-1 Receptor Agonists (GLP-1 RAs): A Pan-Steatotic Liver Disease Treatment?. Biomedicines, 13.","DOI":"10.3390\/biomedicines13071516"},{"key":"ref_11","doi-asserted-by":"crossref","unstructured":"Cannavaro, D., Leva, F., Caturano, A., Berra, C.C., Bonfrate, L., and Conte, C. (2025). Optimizing Body Composition During Weight Loss: The Role of Amino Acid Supplementation. Nutrients, 17.","DOI":"10.3390\/nu17122000"},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"e13841","DOI":"10.1111\/obr.13841","article-title":"Strategies for minimizing muscle loss during use of incretin-mimetic drugs for treatment of obesity","volume":"26","author":"Mechanick","year":"2025","journal-title":"Obes. Rev."},{"key":"ref_13","first-page":"109123","article-title":"Saving muscle while losing weight: A vital strategy for sustainable results while on glucagon-like peptide-1 related drugs","volume":"16","author":"Ruzic","year":"2025","journal-title":"World J. Diabetes"},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"2199","DOI":"10.2337\/dbi25-0001","article-title":"The Benefits of Exercise Training in Combination With Weight Loss Therapies","volume":"74","author":"Jiang","year":"2025","journal-title":"Diabetes"},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1001\/jama.2024.6586","article-title":"Is Weight Loss-Induced Muscle Mass Loss Clinically Relevant?","volume":"332","author":"Conte","year":"2024","journal-title":"JAMA"},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1038\/s44324-024-00030-5","article-title":"Incretin-based therapies for the treatment of obesity-related diseases","volume":"2","author":"Caruso","year":"2024","journal-title":"NPJ Metab. Health Dis."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"200","DOI":"10.2337\/diab.33.2.200","article-title":"The human glucagon gene is located on chromosome 2","volume":"33","author":"Tricoli","year":"1984","journal-title":"Diabetes"},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1152\/physrev.00013.2014","article-title":"Physiology of proglucagon peptides: Role of glucagon and GLP-1 in health and disease","volume":"95","author":"Sandoval","year":"2015","journal-title":"Physiol. Rev."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"2131","DOI":"10.1053\/j.gastro.2007.03.054","article-title":"Biology of incretins: GLP-1 and GIP","volume":"132","author":"Baggio","year":"2007","journal-title":"Gastroenterology"},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"252","DOI":"10.2337\/diabetes.52.2.252","article-title":"Role of leptin in the regulation of glucagon-like peptide-1 secretion","volume":"52","author":"Anini","year":"2003","journal-title":"Diabetes"},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1016\/S0167-0115(03)00125-3","article-title":"GLP-1 and GIP are colocalized in a subset of endocrine cells in the small intestine","volume":"114","author":"Mortensen","year":"2003","journal-title":"Regul. Pept."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"3169","DOI":"10.1210\/endo-128-6-3169","article-title":"Secretion of proglucagon-derived peptides in response to intestinal luminal nutrients","volume":"128","author":"Roberge","year":"1991","journal-title":"Endocrinology"},{"key":"ref_23","first-page":"952","article-title":"Degradation of glucagon-like peptide-1 by human plasma in vitro yields an N-terminally truncated peptide that is a major endogenous metabolite in vivo","volume":"80","author":"Deacon","year":"1995","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1007\/s00125-005-0098-y","article-title":"The metabolite generated by dipeptidyl-peptidase 4 metabolism of glucagon-like peptide-1 has no influence on plasma glucose levels in patients with type 2 diabetes","volume":"49","author":"Zander","year":"2006","journal-title":"Diabetologia"},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1111\/dom.12593","article-title":"Gastrointestinal actions of glucagon-like peptide-1-based therapies: Glycaemic control beyond the pancreas","volume":"18","author":"Smits","year":"2016","journal-title":"Diabetes Obes. Metab."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1016\/S2213-8587(15)00482-9","article-title":"The incretin effect in healthy individuals and those with type 2 diabetes: Physiology, pathophysiology, and response to therapeutic interventions","volume":"4","author":"Nauck","year":"2016","journal-title":"Lancet Diabetes Endocrinol."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1146\/annurev.med.57.110104.115624","article-title":"Therapeutic approaches to preserve islet mass in type 2 diabetes","volume":"57","author":"Baggio","year":"2006","journal-title":"Annu. Rev. Med."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1016\/j.mce.2008.08.012","article-title":"The incretin system and its role in type 2 diabetes mellitus","volume":"297","author":"Holst","year":"2009","journal-title":"Mol. Cell. Endocrinol."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"S251","DOI":"10.2337\/dc11-s227","article-title":"Loss of incretin effect is a specific, important, and early characteristic of type 2 diabetes","volume":"34","author":"Holst","year":"2011","journal-title":"Diabetes Care"},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"826","DOI":"10.1210\/jcem-37-5-826","article-title":"Stimulation of insulin secretion by gastric inhibitory polypeptide in man","volume":"37","author":"Dupre","year":"1973","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"11050","DOI":"10.1074\/jbc.M601203200","article-title":"Prohormone convertase 1\/3 is essential for processing of the glucose-dependent insulinotropic polypeptide precursor","volume":"281","author":"Ugleholdt","year":"2006","journal-title":"J. Biol. Chem."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"170213","DOI":"10.1016\/j.peptides.2019.170213","article-title":"The role of GIP in alpha-cells and glucagon secretion","volume":"125","author":"El","year":"2020","journal-title":"Peptides"},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"1533317520953041","DOI":"10.1177\/1533317520953041","article-title":"The Dual GLP-1\/GIP Receptor Agonist DA4-JC Shows Superior Protective Properties Compared to the GLP-1 Analogue Liraglutide in the APP\/PS1 Mouse Model of Alzheimer\u2019s Disease","volume":"35","author":"Maskery","year":"2020","journal-title":"Am. J. Alzheimers Dis. Other Dementiasr"},{"key":"ref_34","doi-asserted-by":"crossref","unstructured":"Nogi, Y., Nagashima, M., Terasaki, M., Nohtomi, K., Watanabe, T., and Hirano, T. (2012). Glucose-dependent insulinotropic polypeptide prevents the progression of macrophage-driven atherosclerosis in diabetic apolipoprotein E-null mice. PLoS ONE, 7.","DOI":"10.1371\/journal.pone.0035683"},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"2649","DOI":"10.1007\/s00125-011-2241-2","article-title":"Native incretins prevent the development of atherosclerotic lesions in apolipoprotein E knockout mice","volume":"54","author":"Nagashima","year":"2011","journal-title":"Diabetologia"},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"E773","DOI":"10.1152\/ajpendo.00507.2003","article-title":"Glucose-dependent insulinotropic peptide: Differential effects on hepatic artery vs. portal vein endothelial cells","volume":"286","author":"Ding","year":"2004","journal-title":"Am. J. Physiol. Endocrinol. Metab."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"3261","DOI":"10.1210\/clinem\/dgac542","article-title":"GIP Affects Hepatic Fat and Brown Adipose Tissue Thermogenesis but Not White Adipose Tissue Transcriptome in Type 1 Diabetes","volume":"107","author":"Heimburger","year":"2022","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"ref_38","doi-asserted-by":"crossref","unstructured":"Goralska, J., Razny, U., Polus, A., Dziewonska, A., Gruca, A., Zdzienicka, A., Dembinska-Kiec, A., Solnica, B., Micek, A., and Kapusta, M. (2020). Enhanced GIP Secretion in Obesity Is Associated with Biochemical Alteration and miRNA Contribution to the Development of Liver Steatosis. Nutrients, 12.","DOI":"10.3390\/nu12020476"},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"170208","DOI":"10.1016\/j.peptides.2019.170208","article-title":"The influence of Glucose-dependent Insulinotropic Polypeptide (GIP) on human adipose tissue and fat metabolism: Implications for obesity, type 2 diabetes and Non-Alcoholic Fatty Liver Disease (NAFLD)","volume":"125","author":"Thondam","year":"2020","journal-title":"Peptides"},{"key":"ref_40","doi-asserted-by":"crossref","unstructured":"Donohoe, F., Wilkinson, M., Baxter, E., and Brennan, D.J. (2020). Mitogen-Activated Protein Kinase (MAPK) and Obesity-Related Cancer. Int. J. Mol. Sci., 21.","DOI":"10.3390\/ijms21041241"},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"1852","DOI":"10.2337\/dbi22-0004","article-title":"The Liver-alpha-Cell Axis in Health and in Disease","volume":"71","author":"Richter","year":"2022","journal-title":"Diabetes"},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"646","DOI":"10.1006\/bbrc.1995.1236","article-title":"The role of prohormone convertases PC1 (PC3) and PC2 in the cell-specific processing of proglucagon","volume":"207","author":"Mineo","year":"1995","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"E671","DOI":"10.1152\/ajpendo.00492.2002","article-title":"Glucagon and regulation of glucose metabolism","volume":"284","author":"Jiang","year":"2003","journal-title":"Am. J. Physiol. Endocrinol. Metab."},{"key":"ref_44","doi-asserted-by":"crossref","unstructured":"Janah, L., Kjeldsen, S., Galsgaard, K.D., Winther-Sorensen, M., Stojanovska, E., Pedersen, J., Knop, F.K., Holst, J.J., and Wewer Albrechtsen, N.J. (2019). Glucagon Receptor Signaling and Glucagon Resistance. Int. J. Mol. Sci., 20.","DOI":"10.3390\/ijms20133314"},{"key":"ref_45","doi-asserted-by":"crossref","unstructured":"Kimura, T., Pydi, S.P., Pham, J., and Tanaka, N. (2020). Metabolic Functions of G Protein-Coupled Receptors in Hepatocytes-Potential Applications for Diabetes and NAFLD. Biomolecules, 10.","DOI":"10.3390\/biom10101445"},{"key":"ref_46","doi-asserted-by":"crossref","unstructured":"Kleinert, M., Sachs, S., Habegger, K.M., Hofmann, S.M., and Muller, T.D. (2019). Glucagon Regulation of Energy Expenditure. Int. J. Mol. Sci., 20.","DOI":"10.3390\/ijms20215407"},{"key":"ref_47","doi-asserted-by":"crossref","unstructured":"Martinez, M.S., Manzano, A., Olivar, L.C., Nava, M., Salazar, J., D\u2019Marco, L., Ortiz, R., Chacin, M., Guerrero-Wyss, M., and Cabrera de Bravo, M. (2021). The Role of the alpha Cell in the Pathogenesis of Diabetes: A World beyond the Mirror. Int. J. Mol. Sci., 22.","DOI":"10.3390\/ijms22179504"},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"990s","DOI":"10.1093\/jn\/127.5.990S","article-title":"Sarcopenia: Origins and clinical relevance","volume":"127","author":"Rosenberg","year":"1997","journal-title":"J. Nutr."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"707","DOI":"10.1139\/H10-067","article-title":"Evolution of sarcopenia research","volume":"35","author":"Janssen","year":"2010","journal-title":"Appl. Physiol. Nutr. Metab."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1093\/ageing\/afy169","article-title":"Sarcopenia: Revised European consensus on definition and diagnosis","volume":"48","author":"Bahat","year":"2019","journal-title":"Age Ageing"},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"2636","DOI":"10.1016\/S0140-6736(19)31138-9","article-title":"Sarcopenia","volume":"393","author":"Sayer","year":"2019","journal-title":"Lancet"},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1002\/jcsm.12411","article-title":"Sarcopenia and its association with falls and fractures in older adults: A systematic review and meta-analysis","volume":"10","author":"Yeung","year":"2019","journal-title":"J. Cachexia Sarcopenia Muscle"},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"155533","DOI":"10.1016\/j.metabol.2023.155533","article-title":"Epidemiology of sarcopenia: Prevalence, risk factors, and consequences","volume":"144","author":"Yuan","year":"2023","journal-title":"Metabolism"},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"155557","DOI":"10.1016\/j.metabol.2023.155557","article-title":"Sarcopenia in youth","volume":"144","author":"Jung","year":"2023","journal-title":"Metabolism"},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1080\/17474124.2024.2374472","article-title":"From NAFLD to MASLD: What does it mean?","volume":"18","author":"Chrysavgis","year":"2024","journal-title":"Expert Rev. Gastroenterol. Hepatol."},{"key":"ref_56","first-page":"s176","article-title":"Obesity: Definition, comorbidities, causes, and burden","volume":"22","author":"Apovian","year":"2016","journal-title":"Am. J. Manag. Care"},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1159\/000521241","article-title":"Definition and Diagnostic Criteria for Sarcopenic Obesity: ESPEN and EASO Consensus Statement","volume":"15","author":"Donini","year":"2022","journal-title":"Obes. Facts"},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"4633","DOI":"10.1016\/j.clnu.2021.06.009","article-title":"Global prevalence of sarcopenic obesity in older adults: A systematic review and meta-analysis","volume":"40","author":"Gao","year":"2021","journal-title":"Clin. Nutr."},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"Fso127","DOI":"10.4155\/fsoa-2016-0028","article-title":"Physical activity and sarcopenic obesity: Definition, assessment, prevalence and mechanism","volume":"2","author":"Lee","year":"2016","journal-title":"Future Sci. OA"},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1111\/j.1749-6632.2000.tb06498.x","article-title":"Body composition in healthy aging","volume":"904","author":"Baumgartner","year":"2000","journal-title":"Ann. NY Acad. Sci."},{"key":"ref_61","doi-asserted-by":"crossref","unstructured":"Wang, M., Tan, Y., Shi, Y., Wang, X., Liao, Z., and Wei, P. (2020). Diabetes and Sarcopenic Obesity: Pathogenesis, Diagnosis, and Treatments. Front. Endocrinol., 11.","DOI":"10.3389\/fendo.2020.00568"},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"1652","DOI":"10.2337\/dc10-0107","article-title":"Sarcopenic obesity: Prevalence and association with metabolic syndrome in the Korean Longitudinal Study on Health and Aging (KLoSHA)","volume":"33","author":"Lim","year":"2010","journal-title":"Diabetes Care"},{"key":"ref_63","doi-asserted-by":"crossref","unstructured":"Ebadi, M., Tsien, C., Bhanji, R.A., Dunichand-Hoedl, A.R., Rider, E., Motamedrad, M., Mazurak, V.C., Baracos, V., and Montano-Loza, A.J. (2022). Myosteatosis in Cirrhosis: A Review of Diagnosis, Pathophysiological Mechanisms and Potential Interventions. Cells, 11.","DOI":"10.3390\/cells11071216"},{"key":"ref_64","first-page":"260","article-title":"Epidemiology of myosteatosis","volume":"13","author":"Miljkovic","year":"2010","journal-title":"Curr. Opin. Clin. Nutr. Metab. Care"},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"482","DOI":"10.4093\/dmj.2020.0277","article-title":"Computed Tomography-Derived Myosteatosis and Metabolic Disorders","volume":"45","author":"Miljkovic","year":"2021","journal-title":"Diabetes Metab. J."},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"7863","DOI":"10.1096\/fj.201802457RR","article-title":"Reduced mitochondrial lipid oxidation leads to fat accumulation in myosteatosis","volume":"33","author":"Gumucio","year":"2019","journal-title":"FASEB J."},{"key":"ref_67","first-page":"32207258","article-title":"Impact of Skeletal Muscle Mass on Metabolic Health","volume":"35","author":"Kim","year":"2020","journal-title":"Endocrinol. Metab."},{"key":"ref_68","doi-asserted-by":"crossref","unstructured":"Izzo, A., Massimino, E., Riccardi, G., and Della Pepa, G. (2021). A Narrative Review on Sarcopenia in Type 2 Diabetes Mellitus: Prevalence and Associated Factors. Nutrients, 13.","DOI":"10.3390\/nu13010183"},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1016\/j.clnesp.2023.09.920","article-title":"Prevalence of sarcopenic obesity in patients with diabetes and adverse outcomes: A systematic review and meta-analysis","volume":"58","author":"Zhou","year":"2023","journal-title":"Clin. Nutr. ESPEN"},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"7330133","DOI":"10.1155\/2024\/7330133","article-title":"Association between Metabolic Syndrome and Musculoskeletal Status: A Cross-Sectional Study of NHANES","volume":"2024","author":"Shi","year":"2024","journal-title":"Int. J. Endocrinol."},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"140","DOI":"10.4093\/dmj.2016.40.2.140","article-title":"Hyperglycemia Is Associated with Impaired Muscle Quality in Older Men with Diabetes: The Korean Longitudinal Study on Health and Aging","volume":"40","author":"Yoon","year":"2016","journal-title":"Diabetes Metab. J."},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"82","DOI":"10.2337\/dc14-1166","article-title":"Hyperglycemia predicts persistently lower muscle strength with aging","volume":"38","author":"Kalyani","year":"2015","journal-title":"Diabetes Care"},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"1057","DOI":"10.2147\/DMSO.S186600","article-title":"Sarcopenia and type 2 diabetes mellitus: A bidirectional relationship","volume":"12","author":"Mesinovic","year":"2019","journal-title":"Diabetes Metab. Syndr. Obes."},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1016\/j.ecl.2023.02.004","article-title":"Metabolic-Associated Fatty Liver Disease and Sarcopenia","volume":"52","author":"Bali","year":"2023","journal-title":"Endocrinol. Metab. Clin. North Am."},{"key":"ref_75","first-page":"234","article-title":"Frailty in metabolic syndrome, focusing on nonalcoholic fatty liver disease","volume":"35","author":"Karakousis","year":"2022","journal-title":"Ann. Gastroenterol."},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1186\/s12933-018-0755-3","article-title":"Low muscle quality in Japanese type 2 diabetic patients with visceral fat accumulation","volume":"17","author":"Murai","year":"2018","journal-title":"Cardiovasc. Diabetol."},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"2118","DOI":"10.1002\/oby.20346","article-title":"Abdominal myosteatosis is independently associated with hyperinsulinemia and insulin resistance among older men without diabetes","volume":"21","author":"Miljkovic","year":"2013","journal-title":"Obesity"},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"e3513","DOI":"10.1002\/dmrr.3513","article-title":"Association between type 2 diabetes and skeletal muscle quality assessed by abdominal computed tomography scan","volume":"38","author":"Kim","year":"2022","journal-title":"Diabetes Metab. Res. Rev."},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1111\/iju.15304","article-title":"Myosteatosis as a novel predictor of new-onset diabetes mellitus after kidney transplantation","volume":"31","author":"Wakamiya","year":"2024","journal-title":"Int. J. Urol."},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1111\/ggi.12579","article-title":"Association of sarcopenic obesity with the risk of all-cause mortality: A meta-analysis of prospective cohort studies","volume":"16","author":"Tian","year":"2016","journal-title":"Geriatr. Gerontol. Int."},{"key":"ref_81","doi-asserted-by":"crossref","first-page":"e1385","DOI":"10.1210\/clinem\/dgae567","article-title":"Myosteatosis predicts bariatric surgery response: A longitudinal study in patients with morbid obesity","volume":"110","author":"Han","year":"2024","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"ref_82","doi-asserted-by":"crossref","first-page":"1966","DOI":"10.1097\/HEP.0000000000000520","article-title":"A multisociety Delphi consensus statement on new fatty liver disease nomenclature","volume":"78","author":"Rinella","year":"2023","journal-title":"Hepatology"},{"key":"ref_83","doi-asserted-by":"crossref","first-page":"100963","DOI":"10.1016\/j.jhepr.2023.100963","article-title":"Myosteatosis: Diagnosis, pathophysiology and consequences in metabolic dysfunction-associated steatotic liver disease","volume":"6","author":"Henin","year":"2024","journal-title":"JHEP Rep."},{"key":"ref_84","doi-asserted-by":"crossref","first-page":"688","DOI":"10.1007\/s12072-023-10632-8","article-title":"Prevalence and impact on the outcome of myosteatosis in patients with cirrhosis: A systematic review and meta-analysis","volume":"18","author":"Kamiliou","year":"2024","journal-title":"Hepatol. Int."},{"key":"ref_85","doi-asserted-by":"crossref","first-page":"2005","DOI":"10.1016\/j.clnu.2024.07.006","article-title":"The prevalence and effects of sarcopenia in patients with metabolic dysfunction-associated steatotic liver disease (MASLD): A systematic review and meta-analysis","volume":"43","author":"Li","year":"2024","journal-title":"Clin. Nutr."},{"key":"ref_86","doi-asserted-by":"crossref","first-page":"388","DOI":"10.1016\/j.cgh.2022.01.020","article-title":"Myosteatosis, but not Sarcopenia, Predisposes NAFLD Subjects to Early Steatohepatitis and Fibrosis Progression","volume":"21","author":"Hsieh","year":"2023","journal-title":"Clin. Gastroenterol. Hepatol."},{"key":"ref_87","doi-asserted-by":"crossref","first-page":"1281","DOI":"10.1016\/j.clnu.2022.03.022","article-title":"Skeletal muscle mass and abdominal obesity are independent predictors of hepatic steatosis and interact to predict ten-year cardiovascular disease incidence: Data from the ATTICA cohort study","volume":"41","author":"Kouvari","year":"2022","journal-title":"Clin. Nutr."},{"key":"ref_88","doi-asserted-by":"crossref","first-page":"e14108","DOI":"10.1111\/eci.14108","article-title":"The association of testosterone with sarcopenia and frailty in chronic liver disease","volume":"54","author":"Chrysavgis","year":"2024","journal-title":"Eur. J. Clin. Investig."},{"key":"ref_89","doi-asserted-by":"crossref","unstructured":"Jeromson, S., Baranowski, B., Akcan, M., Waters, B.D., Eisner, K., Bellucci, A., Trang, S., Abolhassani, A., Tello-Palencia, M.A., and Schweitzer, A. (2025). Semaglutide impacts skeletal muscle to a similar extent as caloric restriction in mice with diet-induced obesity. J. Physiol., 40982727.","DOI":"10.1113\/JP289449"},{"key":"ref_90","doi-asserted-by":"crossref","first-page":"1619","DOI":"10.1016\/j.cmet.2025.07.004","article-title":"Unexpected effects of semaglutide on skeletal muscle mass and force-generating capacity in mice","volume":"37","author":"Karasawa","year":"2025","journal-title":"Cell Metab."},{"key":"ref_91","doi-asserted-by":"crossref","first-page":"101880","DOI":"10.1016\/j.molmet.2024.101880","article-title":"Antibody blockade of activin type II receptors preserves skeletal muscle mass and enhances fat loss during GLP-1 receptor agonism","volume":"80","author":"Nunn","year":"2024","journal-title":"Mol. Metab."},{"key":"ref_92","doi-asserted-by":"crossref","first-page":"2433","DOI":"10.2147\/DMSO.S425642","article-title":"GLP-1RA Liraglutide and Semaglutide Improves Obesity-Induced Muscle Atrophy via SIRT1 Pathway","volume":"16","author":"Xiang","year":"2023","journal-title":"Diabetes Metab. Syndr. Obes."},{"key":"ref_93","doi-asserted-by":"crossref","first-page":"E355","DOI":"10.1152\/ajpendo.00283.2013","article-title":"GLP-1 increases microvascular recruitment but not glucose uptake in human and rat skeletal muscle","volume":"306","author":"Sjoberg","year":"2014","journal-title":"Am. J. Physiol. Endocrinol. Metab."},{"key":"ref_94","doi-asserted-by":"crossref","first-page":"bvad074","DOI":"10.1210\/jendso\/bvad074","article-title":"Chronic Semaglutide Treatment in Rats Leads to Daily Excessive Concentration-Dependent Sucrose Intake","volume":"7","author":"Cawthon","year":"2023","journal-title":"J. Endocr. Soc."},{"key":"ref_95","doi-asserted-by":"crossref","first-page":"102682","DOI":"10.1016\/j.jbc.2022.102682","article-title":"Glucagon-like peptide-1 analog liraglutide leads to multiple metabolic alterations in diet-induced obese mice","volume":"298","author":"Park","year":"2022","journal-title":"J. Biol. Chem."},{"key":"ref_96","doi-asserted-by":"crossref","first-page":"e13677","DOI":"10.1002\/jcsm.13677","article-title":"The Effects of Glucagon-Like Peptide-1 Receptor Agonists on Mitochondrial Function Within Skeletal Muscle: A Systematic Review","volume":"16","author":"Old","year":"2025","journal-title":"J. Cachexia Sarcopenia Muscle"},{"key":"ref_97","doi-asserted-by":"crossref","first-page":"119300","DOI":"10.1016\/j.bbamcr.2022.119300","article-title":"GLP-1 regulates exercise endurance and skeletal muscle remodeling via GLP-1R\/AMPK pathway","volume":"1869","author":"Wu","year":"2022","journal-title":"Biochim. Biophys. Acta Mol. Cell. Res."},{"key":"ref_98","doi-asserted-by":"crossref","first-page":"154044","DOI":"10.1016\/j.metabol.2019.154044","article-title":"Long acting GLP-1 analog liraglutide ameliorates skeletal muscle atrophy in rodents","volume":"103","author":"Gurjar","year":"2020","journal-title":"Metabolism"},{"key":"ref_99","doi-asserted-by":"crossref","first-page":"903","DOI":"10.1002\/jcsm.12434","article-title":"Amelioration of muscle wasting by glucagon-like peptide-1 receptor agonist in muscle atrophy","volume":"10","author":"Hong","year":"2019","journal-title":"J. Cachexia Sarcopenia Muscle"},{"key":"ref_100","doi-asserted-by":"crossref","first-page":"2682","DOI":"10.1056\/NEJMoa040933","article-title":"Myostatin mutation associated with gross muscle hypertrophy in a child","volume":"350","author":"Schuelke","year":"2004","journal-title":"N. Engl. J. Med."},{"key":"ref_101","doi-asserted-by":"crossref","first-page":"e2033457","DOI":"10.1001\/jamanetworkopen.2020.33457","article-title":"Effect of Bimagrumab vs Placebo on Body Fat Mass Among Adults With Type 2 Diabetes and Obesity: A Phase 2 Randomized Clinical Trial","volume":"4","author":"Heymsfield","year":"2021","journal-title":"JAMA Netw. Open"},{"key":"ref_102","doi-asserted-by":"crossref","unstructured":"Chrysavgis, L.G., Kazanas, S., Bafa, K., Rozani, S., Koloutsou, M.E., and Cholongitas, E. (2024). Glucagon-like Peptide 1, Glucose-Dependent Insulinotropic Polypeptide, and Glucagon Receptor Agonists in Metabolic Dysfunction-Associated Steatotic Liver Disease: Novel Medication in New Liver Disease Nomenclature. Int. J. Mol. Sci., 25.","DOI":"10.3390\/ijms25073832"},{"key":"ref_103","first-page":"e51352","article-title":"Glucagon-Like Peptide-1 Receptor Agonists in the Treatment of Idiopathic Inflammatory Myopathy: From Mechanisms of Action to Clinical Applications","volume":"15","author":"Rajagopal","year":"2023","journal-title":"Cureus"},{"key":"ref_104","doi-asserted-by":"crossref","first-page":"101533","DOI":"10.1016\/j.molmet.2022.101533","article-title":"Next generation GLP-1\/GIP\/glucagon triple agonists normalize body weight in obese mice","volume":"63","author":"Knerr","year":"2022","journal-title":"Mol. Metab."},{"key":"ref_105","doi-asserted-by":"crossref","first-page":"890","DOI":"10.1038\/ijo.2011.203","article-title":"Safety, tolerability and sustained weight loss over 2 years with the once-daily human GLP-1 analogue, liraglutide","volume":"36","author":"Astrup","year":"2012","journal-title":"Int. J. Obes."},{"key":"ref_106","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1111\/dom.14255","article-title":"Effects of oral semaglutide on energy intake, food preference, appetite, control of eating and body weight in subjects with type 2 diabetes","volume":"23","author":"Gibbons","year":"2021","journal-title":"Diabetes Obes. Metab."},{"key":"ref_107","doi-asserted-by":"crossref","first-page":"1915","DOI":"10.2337\/diacare.27.8.1915","article-title":"The effect of liraglutide, a long-acting glucagon-like peptide 1 derivative, on glycemic control, body composition, and 24-h energy expenditure in patients with type 2 diabetes","volume":"27","author":"Harder","year":"2004","journal-title":"Diabetes Care"},{"key":"ref_108","doi-asserted-by":"crossref","first-page":"1742","DOI":"10.1111\/dom.14090","article-title":"Liraglutide treatment in overweight and obese patients with type 1 diabetes: A 26-week randomized controlled trial; mechanisms of weight loss","volume":"22","author":"Ghanim","year":"2020","journal-title":"Diabetes Obes. Metab."},{"key":"ref_109","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1111\/acps.12711","article-title":"No cognitive-enhancing effect of GLP-1 receptor agonism in antipsychotic-treated, obese patients with schizophrenia","volume":"136","author":"Ishoy","year":"2017","journal-title":"Acta Psychiatr. Scand."},{"key":"ref_110","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1111\/dom.13063","article-title":"Beyond glycaemic control: A cross-over, double-blinded, 24-week intervention with liraglutide in type 1 diabetes","volume":"20","author":"Dube","year":"2018","journal-title":"Diabetes Obes. Metab."},{"key":"ref_111","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1111\/dom.12797","article-title":"Near-normalization of glycaemic control with glucagon-like peptide-1 receptor agonist treatment combined with exercise in patients with type 2 diabetes","volume":"19","author":"Mensberg","year":"2017","journal-title":"Diabetes Obes. Metab."},{"key":"ref_112","doi-asserted-by":"crossref","first-page":"2340","DOI":"10.1111\/dom.15113","article-title":"Effect of the glucagon-like peptide-1 receptor agonist liraglutide, compared to caloric restriction, on appetite, dietary intake, body fat distribution and cardiometabolic biomarkers: A randomized trial in adults with obesity and prediabetes","volume":"25","author":"Silver","year":"2023","journal-title":"Diabetes Obes. Metab."},{"key":"ref_113","doi-asserted-by":"crossref","first-page":"616","DOI":"10.1016\/j.numecd.2019.12.005","article-title":"Liraglutide decreases energy expenditure and does not affect the fat fraction of supraclavicular brown adipose tissue in patients with type 2 diabetes","volume":"30","author":"Paiman","year":"2020","journal-title":"Nutr. Metab. Cardiovasc. Dis."},{"key":"ref_114","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1111\/jdi.12888","article-title":"Effects of liraglutide, metformin and gliclazide on body composition in patients with both type 2 diabetes and non-alcoholic fatty liver disease: A randomized trial","volume":"10","author":"Feng","year":"2019","journal-title":"J. Diabetes Investig."},{"key":"ref_115","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1186\/s12986-018-0295-6","article-title":"Effects of exenatide versus insulin glargine on body composition in overweight and obese T2DM patients: A randomized controlled trial","volume":"15","author":"Yin","year":"2018","journal-title":"Nutr. Metab."},{"key":"ref_116","doi-asserted-by":"crossref","first-page":"998","DOI":"10.2337\/dc22-1710","article-title":"Tirzepatide Reduces Appetite, Energy Intake, and Fat Mass in People With Type 2 Diabetes","volume":"46","author":"Heise","year":"2023","journal-title":"Diabetes Care"},{"key":"ref_117","doi-asserted-by":"crossref","first-page":"1163","DOI":"10.1111\/j.1463-1326.2009.01158.x","article-title":"LEAD-2 and LEAD-3 Study Groups. Weight loss with liraglutide, a once-daily human glucagon-like peptide-1 analogue for type 2 diabetes treatment as monotherapy or added to metformin, is primarily as a result of a reduction in fat tissue","volume":"11","author":"Jendle","year":"2009","journal-title":"Diabetes Obes. Metab."},{"key":"ref_118","doi-asserted-by":"crossref","first-page":"1552","DOI":"10.1210\/clinem\/dgz140","article-title":"GLP-1 Analog Modulates Appetite, Taste Preference, Gut Hormones, and Regional Body Fat Stores in Adults with Obesity","volume":"105","author":"Kadouh","year":"2020","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"ref_119","doi-asserted-by":"crossref","first-page":"1719","DOI":"10.1056\/NEJMoa2028198","article-title":"Healthy Weight Loss Maintenance with Exercise, Liraglutide, or Both Combined","volume":"384","author":"Lundgren","year":"2021","journal-title":"N. Engl. J. Med."},{"key":"ref_120","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1002\/oby.23098","article-title":"Liraglutide Does Not Adversely Impact Fat-Free Mass Loss","volume":"29","author":"Grannell","year":"2021","journal-title":"Obesity"},{"key":"ref_121","doi-asserted-by":"crossref","first-page":"1242","DOI":"10.1111\/dom.12932","article-title":"Effects of once-weekly semaglutide on appetite, energy intake, control of eating, food preference and body weight in subjects with obesity","volume":"19","author":"Blundell","year":"2017","journal-title":"Diabetes Obes. Metab."},{"key":"ref_122","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1007\/s00125-019-05065-8","article-title":"Effects of once-weekly semaglutide vs once-daily canagliflozin on body composition in type 2 diabetes: A substudy of the SUSTAIN 8 randomised controlled clinical trial","volume":"63","author":"McCrimmon","year":"2020","journal-title":"Diabetologia"},{"key":"ref_123","doi-asserted-by":"crossref","first-page":"989","DOI":"10.1056\/NEJMoa2032183","article-title":"Once-Weekly Semaglutide in Adults with Overweight or Obesity","volume":"384","author":"Wilding","year":"2021","journal-title":"N. Engl. J. Med."},{"key":"ref_124","doi-asserted-by":"crossref","first-page":"1734","DOI":"10.2337\/dc09-2361","article-title":"Exenatide affects circulating cardiovascular risk biomarkers independently of changes in body composition","volume":"33","author":"Bunck","year":"2010","journal-title":"Diabetes Care"},{"key":"ref_125","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1056\/NEJMoa2206038","article-title":"Tirzepatide Once Weekly for the Treatment of Obesity","volume":"387","author":"Jastreboff","year":"2022","journal-title":"N. Engl. J. Med."},{"key":"ref_126","doi-asserted-by":"crossref","first-page":"657","DOI":"10.1159\/000545968","article-title":"32nd European Congress on Obesity (ECO 2025)\u2014LATE BREAKING ABSTRACTS","volume":"18","author":"Avcilar","year":"2025","journal-title":"Obes. Facts"},{"key":"ref_127","doi-asserted-by":"crossref","first-page":"482","DOI":"10.1016\/S2213-8587(25)00027-0","article-title":"Tirzepatide and muscle composition changes in people with type 2 diabetes (SURPASS-3 MRI): A post-hoc analysis of a randomised, open-label, parallel-group, phase 3 trial","volume":"13","author":"Sattar","year":"2025","journal-title":"Lancet Diabetes Endocrinol."},{"key":"ref_128","unstructured":"(2025, December 07). Available online: https:\/\/clinicaltrials.gov\/study\/NCT06445075."},{"key":"ref_129","doi-asserted-by":"crossref","first-page":"635","DOI":"10.1056\/NEJMoa2502081","article-title":"Coadministered Cagrilintide and Semaglutide in Adults with Overweight or Obesity","volume":"393","author":"Garvey","year":"2025","journal-title":"N. Engl. J. Med."},{"key":"ref_130","doi-asserted-by":"crossref","first-page":"2215","DOI":"10.1056\/NEJMoa2411528","article-title":"Once-Weekly Mazdutide in Chinese Adults with Obesity or Overweight","volume":"392","author":"Ji","year":"2025","journal-title":"N. Engl. J. Med."},{"key":"ref_131","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1016\/S2213-8587(22)00070-5","article-title":"Effect of tirzepatide versus insulin degludec on liver fat content and abdominal adipose tissue in people with type 2 diabetes (SURPASS-3 MRI): A substudy of the randomised, open-label, parallel-group, phase 3 SURPASS-3 trial","volume":"10","author":"Gastaldelli","year":"2022","journal-title":"Lancet Diabetes Endocrinol."},{"key":"ref_132","doi-asserted-by":"crossref","first-page":"1072","DOI":"10.1002\/jcsm.13445","article-title":"Effect of liraglutide on thigh muscle fat and muscle composition in adults with overweight or obesity: Results from a randomized clinical trial","volume":"15","author":"Pandey","year":"2024","journal-title":"J. Cachexia Sarcopenia Muscle"},{"key":"ref_133","doi-asserted-by":"crossref","first-page":"e62667","DOI":"10.2196\/62667","article-title":"Effect of Semaglutide on Physical Function, Body Composition, and Biomarkers of Aging in Older Adults With Overweight and Insulin Resistance: Protocol for an Open-Labeled Randomized Controlled Trial","volume":"13","author":"Cortes","year":"2024","journal-title":"JMIR Res. Protoc."},{"key":"ref_134","doi-asserted-by":"crossref","unstructured":"Volpe, S., Lisco, G., Racaniello, D., Fanelli, M., Colaianni, V., Vozza, A., Triggiani, V., Sabba, C., Tortorella, C., and De Pergola, G. (2022). Once-Weekly Semaglutide Induces an Early Improvement in Body Composition in Patients with Type 2 Diabetes: A 26-Week Prospective Real-Life Study. Nutrients, 14.","DOI":"10.3389\/fendo.2023.1240263"},{"key":"ref_135","doi-asserted-by":"crossref","unstructured":"Alabadi, B., Civera, M., De la Rosa, A., Martinez-Hervas, S., Gomez-Cabrera, M.C., and Real, J.T. (2023). Low Muscle Mass Is Associated with Poorer Glycemic Control and Higher Oxidative Stress in Older Patients with Type 2 Diabetes. Nutrients, 15.","DOI":"10.3390\/nu15143167"},{"key":"ref_136","doi-asserted-by":"crossref","first-page":"e13574","DOI":"10.1111\/obr.13574","article-title":"GLP-1 analogs and regional adiposity: A systematic review and meta-analysis","volume":"24","author":"Akoumianakis","year":"2023","journal-title":"Obes. Rev."},{"key":"ref_137","doi-asserted-by":"crossref","first-page":"327","DOI":"10.2174\/1573399810666141017153749","article-title":"Physiological mechanisms of action of incretin and insulin in regulating skeletal muscle metabolism","volume":"10","author":"Abdulla","year":"2014","journal-title":"Curr. Diabetes. Rev."},{"key":"ref_138","doi-asserted-by":"crossref","first-page":"465","DOI":"10.3233\/CH-242134","article-title":"Tirzepatide and exercise training in obesity","volume":"87","author":"Marzetti","year":"2024","journal-title":"Clin. Hemorheol. Microcirc."},{"key":"ref_139","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1001\/jama.2021.23619","article-title":"Effect of Weekly Subcutaneous Semaglutide vs Daily Liraglutide on Body Weight in Adults With Overweight or Obesity Without Diabetes: The STEP 8 Randomized Clinical Trial","volume":"327","author":"Rubino","year":"2022","journal-title":"JAMA"},{"key":"ref_140","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1016\/j.physbeh.2017.04.017","article-title":"Daily supplementation of dietary protein improves the metabolic effects of GLP-1-based pharmacotherapy in lean and obese rats","volume":"177","author":"McGrath","year":"2017","journal-title":"Physiol. Behav."},{"key":"ref_141","doi-asserted-by":"crossref","first-page":"102024","DOI":"10.1016\/j.molmet.2024.102024","article-title":"Dietary protein defends lean mass and maintains the metabolic benefits of glucagon receptor agonism in mice","volume":"89","author":"Lopes","year":"2024","journal-title":"Mol. Metab."}],"container-title":["International Journal of Molecular Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1422-0067\/26\/24\/12130\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,17]],"date-time":"2025-12-17T10:44:38Z","timestamp":1765968278000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1422-0067\/26\/24\/12130"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12,17]]},"references-count":141,"journal-issue":{"issue":"24","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["ijms262412130"],"URL":"https:\/\/doi.org\/10.3390\/ijms262412130","relation":{},"ISSN":["1422-0067"],"issn-type":[{"value":"1422-0067","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,12,17]]}}}